CIK 0001750284 · Non-accelerated filer<br>Smaller reporting company
Olema Oncology, Inc.
Sign in to watch- Ticker
- OLMA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 300409740
- Phone
- (415) 651-3316
- Business address
- 365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Olema Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-04 | BVF PARTNERS L P/IL Director | Grant or award · Pre-Funded Warrant | +1,258,027 | $9.08 | $11.4M | 3,055,554 |
| 2024-12-04 | BVF PARTNERS L P/IL Director | Grant or award · Pre-Funded Warrant | +1,047,044 | $9.08 | $9.5M | 2,465,780 |
| 2024-12-04 | BVF PARTNERS L P/IL Director | Grant or award · Pre-Funded Warrant | +160,107 | $9.08 | $1.5M | 313,548 |
| 2024-11-15 | Kovacs Shane William Charles Ch. Operating & Financial Off. | Option exercise | +25,000 | $7.02 | $176K | 510,458 |
| 2024-11-15 | Kovacs Shane William Charles Ch. Operating & Financial Off. | Option exercise · Stock Option (Right to Buy) | −25,000 | 162,000 | ||
| 2024-08-01 | Paradigm Biocapital Advisors LP 10% owner | Sale | −1,870,499 | $14.92 | $27.9M | 4,720,482 |
| 2024-08-01 | Paradigm Biocapital Advisors LP 10% owner | Sale | −529,501 | $14.92 | $7.9M | 783,118 |
| 2024-07-30 | Harmon Cyrus Director | Sale 10b5-1 | −934 | $15.55 | $15K | 751,283 |
| 2024-07-29 | Harmon Cyrus Director | Sale 10b5-1 | −4,066 | $15.58 | $63K | 752,217 |
| 2024-07-11 | Harmon Cyrus Director | Sale 10b5-1 | −5,000 | $12.26 | $61K | 756,283 |
| 2024-06-28 | Harmon Cyrus Director | Sale 10b5-1 | −20,000 | $10.77 | $215K | 761,283 |
| 2024-06-14 | Graham G. Walmsley Director | Grant or award · Stock Option (right to buy) | +23,000 | 23,000 | ||
| 2024-06-14 | RAPPAPORT ANDREW Director | Grant or award · Stock Option (right to buy) | +23,000 | 23,000 | ||
| 2024-06-14 | Larson Yi Director | Grant or award · Stock Option (Right to Buy) | +23,000 | 23,000 | ||
| 2024-06-14 | Hrustanovic Gorjan Director | Grant or award · Stock Option (right to buy) | +23,000 | 23,000 | ||
| 2024-06-14 | Horning Sandra Director | Grant or award · Stock Option (right to buy) | +23,000 | 23,000 | ||
| 2024-06-14 | Harmon Cyrus Director | Grant or award · Stock Option (Right to Buy) | +23,000 | 23,000 | ||
| 2024-06-14 | Garland J. Scott Director | Grant or award · Stock Option (Right to Buy) | +23,000 | 23,000 | ||
| 2024-06-14 | BUTITTA CYNTHIA M Director | Grant or award · Stock Option (right to buy) | +23,000 | 23,000 | ||
| 2024-06-14 | CLARK IAN T Director | Grant or award · Stock Option (right to buy) | +23,000 | 23,000 |
Page 8 of 11 · 207 trades